How effective is genomic tumour profiling for breast cancer?

The test analyses genetic or molecular features in a sample of the tumour. The report may identify a change linked with a targeted medicine, resistance pattern, or possible clinical-trial option. Results can also be non-actionable, meaning that no available treatment is clearly matched to the finding.

Your oncologist combines the profile with tumour size, grade, hormone-receptor and HER2 results, stage, previous treatment and your general health. A result is a decision aid rather than a diagnosis on its own. Tumour biology can differ between areas or change after treatment, so an old sample may not represent the current disease.

Ask what sample will be tested, whether it is adequate, and which decisions the test is intended to inform. Request an explanation of each actionable finding, including the evidence for using a medicine in your situation and the alternatives.

Keep the report with your treatment records. If the cancer returns or progresses, ask whether new tissue or another form of testing would add useful information. Never start, stop or change cancer treatment from a report without discussing it with your oncology team.

Contact your oncology team if a result raises questions about a treatment change or trial referral. Seek urgent help for severe breathlessness, new confusion, uncontrolled pain or a high fever during treatment; genomic profiling does not assess emergencies.

Ask which finding matters most, whether it changes the recommended plan, how certain the match is, and what side effects the proposed treatment may bring. Ask whether the result has implications for relatives or only for the tumour.